Literature DB >> 34611305

Modulation of osteoclastogenesis through adrenomedullin receptors on osteoclast precursors: initiation of differentiation by asymmetric cell division.

Toshio Kukita1, Hidenobu Hiura2,3, Jiong-Yan Gu2, Jing-Qi Zhang2, Yukari Kyumoto-Nakamura2, Norihisa Uehara2, Sara Murata2,3, Soichiro Sonoda2, Takayoshi Yamaza2, Ichiro Takahashi3, Akiko Kukita4.   

Abstract

Adrenomedullin (ADM), a member of the calcitonin family of peptides, is a potent vasodilator and was shown to have the ability to modulate bone metabolism. We have previously found a unique cell surface antigen (Kat1 antigen) expressed in rat osteoclasts, which is involved in the functional regulation of the calcitonin receptor (CTR). Cross-linking of cell surface Kat1 antigen with anti-Kat1 antigen monoclonal antibody (mAbKat1) stimulated osteoclast formation only under conditions suppressed by calcitonin. Here, we found that ADM provoked a significant stimulation in osteoclastogenesis only in the presence of calcitonin; a similar biological effect was seen with mAbKat1 in the bone marrow culture system. This stimulatory effect on osteoclastogenesis mediated by ADM was abolished by the addition of mAbKat1. 125I-labeled rat ADM (125I-ADM)-binding experiments involving micro-autoradiographic studies demonstrated that mononuclear precursors of osteoclasts abundantly expressed ADM receptors, and the specific binding of 125I-ADM was markedly inhibited by the addition of mAbKat1, suggesting a close relationship between the Kat1 antigen and the functional ADM receptors expressed on cells in the osteoclast lineage. ADM receptors were also detected in the osteoclast progenitor cells in the late mitotic phase, in which only one daughter cell of the dividing cell express ADM receptors, suggesting the semiconservative cell division of the osteoclast progenitors in the initiation of osteoclastogenesis. Messenger RNAs for the receptor activity-modifying-protein 1 (RAMP1) and calcitonin receptor-like receptor (CRLR) were expressed in cells in the osteoclast lineage; however, the expression of RAMP2 or RAMP3 was not detected in these cells. It is suggested that the Kat1 antigen is involved in the functional ADM receptor distinct from the general ADM receptor, consisting of CRLR and RAMP2 or RAMP3. Modulation of osteoclastogenesis through functional ADM receptors abundantly expressed on mononuclear osteoclast precursors is supposed to be important in the fine regulation of osteoclast differentiation in a specific osteotrophic hormonal condition with a high level of calcitonin in blood.
© 2021. The Author(s), under exclusive licence to United States and Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34611305     DOI: 10.1038/s41374-021-00633-2

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  4 in total

1.  Novel cell-surface Ag expressed on rat osteoclasts regulating the function of the calcitonin receptor.

Authors:  T Kukita; A Kukita; K Nagata; H Maeda; K Kurisu; T Watanabe; T Iijima
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

2.  Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover.

Authors:  T Kuratani; K Nagata; T Kukita; T Hotokebuchi; A Nakasima; T Iijima
Journal:  Histol Histopathol       Date:  1998-07       Impact factor: 2.303

3.  Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis.

Authors:  Yuanxin Liu; Guilai Zuo; Xin Meng; Xingxiao Gao; Lihai Zhang; Peifu Tang
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

  4 in total
  1 in total

1.  Identification of Novel Genes for Cell Fusion during Osteoclast Formation.

Authors:  Eunjin Cho; Seongmin Cheon; Mina Ding; Kayeong Lim; Sang-Wook Park; Chungoo Park; Tae-Hoon Lee
Journal:  Int J Mol Sci       Date:  2022-06-08       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.